CHRONIC LYMPHOCYTIC LEUKEMIA

This early-stage study tested the safety and initial effectiveness of a new drug called odronextamab in 200 adults with advanced non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is designed to attach to cancer cells and the immune system to help the body fight the c…

This early-phase study tested a new gene therapy approach for patients whose non-Hodgkin lymphoma or chronic lymphocytic leukemia had returned or didn't respond to standard treatments. Researchers modified patients' own immune T-cells in the lab to better recognize and attack the…

This study tested whether giving vitamin D supplements to patients with newly diagnosed lymphoma or leukemia who have low vitamin D levels could help control their cancer. Researchers compared high-dose and low-dose vitamin D against no treatment to see if it improved how long pa…

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …

This study tested a combination of three medications—ofatumumab, methylprednisolone, and lenalidomide—for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal was to see if this treatment could effectively control the c…

This study tested a combination of three medicines—ibrutinib, fludarabine, and pembrolizumab—for adults with a hard-to-treat form of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if using these drugs together could achieve a complete …

This study tested a combination of two drugs, idelalisib and ofatumumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not yet received treatment. The goal was to see if using these drugs together was safe and effective at controll…

This study tested a new oral medication called pirtobrutinib for people with chronic lymphocytic leukemia or other B-cell lymphomas that had stopped responding to standard treatments. The main goals were to find a safe and effective dose and to see if the drug could shrink tumors…

This early-stage study tested the safety and initial effectiveness of combining the drug acalabrutinib with other cancer medications for patients with chronic lymphocytic leukemia (CLL) and related blood cancers. It involved 69 patients, some who had been treated before and some …

This early-stage study tested the safety and highest tolerable dose of a new, genetically modified immune cell therapy called PRGN-3007 UltraCAR-T in adults with advanced blood cancers and triple-negative breast cancer. The main goal was to see how much of the treatment patients …

This study tested whether a combination of two drugs, ibrutinib and obinutuzumab, is safe and effective for treating chronic lymphocytic leukemia (CLL) in older adults or those too frail for standard chemotherapy. It involved 32 people with previously untreated CLL. The goal was …

This early-stage study tested the safety of adding a common cholesterol-lowering drug (pitavastatin) to a standard leukemia treatment (venetoclax). It involved 6 adults with either chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find the s…

This study aimed to check the safety of giving the experimental drug cirmtuzumab for 6 to 12 months. It involved only 3 people with chronic lymphocytic leukemia (CLL) who had safely taken the drug in a previous trial. The main goal was to see if this longer treatment schedule was…

This first-in-human study tested a new oral drug called BR101801 in adults with advanced blood cancers that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early s…

This early-stage study tested a new cell therapy called IOV-2001 for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that had returned or stopped responding to standard drugs. The main goals were to find a safe dose and see if the treatment could shrink t…

This large, global study aimed to understand the safety and effectiveness of the drug acalabrutinib for adults with chronic lymphocytic leukemia (CLL). It included over 550 people, including those newly diagnosed, those whose cancer returned, and those who had taken a similar dru…

This study looked at how well a standard treatment combination works for Japanese adults with relapsed chronic lymphocytic leukemia (CLL) in real-world clinics. It followed 89 patients who took venetoclax pills, with or without rituximab infusions, for two years. The main goal wa…

This study tested a 15-month treatment plan for adults newly diagnosed with chronic lymphocytic leukemia (CLL), a type of blood cancer. It combined three drugs: bendamustine and rituximab given first, followed by a year of the pill venetoclax. The goal was to see how well this se…

This study tested if starting a drug called ibrutinib earlier could better control a type of blood cancer called chronic lymphocytic leukemia (CLL) in patients who are at high risk for the disease getting worse but don't yet have symptoms. The usual approach is to wait until symp…

This study tested a two-step, lower-intensity stem cell transplant for patients with high-risk blood cancers like leukemia and lymphoma. The goal was to use milder chemotherapy and radiation before the transplant to reduce side effects while still allowing the donor's immune cell…

This study tested whether the drug acalabrutinib could help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people whose cancer had returned after treatment or who had a specific high-risk genetic change called 17p deletion. The trial involved 48…

This study tested whether regular infusions of Panzyga (an antibody product) could prevent serious infections in adults with chronic lymphocytic leukemia (CLL) who have low antibody levels. 247 participants were randomly assigned to receive either Panzyga or a placebo infusion ev…

This study aimed to understand how often patients with chronic lymphocytic leukemia or multiple myeloma experience financial difficulty due to their cancer treatment. Researchers surveyed 218 patients and their doctors to measure the financial burden, identify what types of costs…

This study aimed to find early warning signs in the blood to predict when the drug ibrutinib might stop working for patients with a high-risk form of chronic lymphocytic leukemia (CLL). Researchers observed 56 patients with a specific genetic change (TP53 mutation) who were start…